ELINOGREL

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H15ClFN5O5S2
Molecular Weight	523.945
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC1=CC2=C(C=C1F)C(=O)N(C(=O)N2)C3=CC=C(NC(=O)NS(=O)(=O)C4=CC=C(Cl)S4)C=C3

InChI

InChIKey=LGSDFTPAICUONK-UHFFFAOYSA-N

InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)

HIDE SMILES / InChI

Molecular Formula	C20H15ClFN5O5S2
Molecular Weight	523.945
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20608816
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800022611 | http://www.wikidoc.org/index.php/Elinogrel

Elinogrel, previously known as PRT060128 or PRT128, is a direct-acting, reversible P2Y12 inhibitor for both intravenous and oral administration. Elinogrel has been tested in 2 phase II studies for the treatment of acute coronary syndrome, myocardial infarction and prevention of secondary thrombotic events. Elinogrel therapy was associated with an increased incidence of dyspnea and incidence of elevated liver transaminases. The development of the drug was terminated in January 2012 by Novartis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Purinergic receptor P2Y12 23 Target ID: CHEMBL2001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20608816	Antagonist 2849		23.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Myocardial infarction 125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19958867	Primary		Phase II 1147	Unknown Approved Use Unknown
Percutaneous coronary intervention 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22647518	Preventing		Phase II 1147	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22647518	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22647518	Disc. AE: Dyspnea... AEs leading to discontinuation/dose reduction: Dyspnea (grade 1-2, 1%) Sources: https://pubmed.ncbi.nlm.nih.gov/22647518

AEs

AE	Significance	Dose	Population
Dyspnea	grade 1-2, 1% Disc. AE	150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22647518	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22647518

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00H1KW	https://www.1pchem.com/search?query=1P00H1KW
Chem Scene	CS-0002993	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0002993
Compound Cloud	16066663
Compound Cloud	23718927
Hairui	HR110297	http://www.hairuichem.com/en/product/search.do?q=HR110297
MedChem Express	HY-11021	https://www.medchemexpress.com/search.html?q=HY-11021&ft=&fa=&fp=
MolPort	MolPort-035-941-202	https://www.molport.com/shop/molecule-link/MolPort-035-941-202
MuseChem	I006640	https://www.musechem.com/product/I006640.html
Tocris	5316	https://www.tocris.com/search.php?Type=QuickSearch&Value=5316

PubMed

Title	Date	PubMed
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.	2010-11-02	20800407
Newer antithrombotic drugs.	2010-10	21572750
State of the art of new P2Y12 antagonists.	2010-10	20177818
Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?	2010-08	20570595
Elinogrel: pharmacological principles, preclinical and early phase clinical testing.	2010-07	20608816
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).	2010-07	20598974
Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.	2010-06-01	20539844
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.	2010-04	20299391
Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events.	2010-03	20178048
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.	2010-02-01	20050853
Limitations of current therapies to prevent thrombosis: a need for novel strategies.	2010-02	20094648
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.	2010-01	19817997
Emerging antiplatelet agents, differential pharmacology, and clinical utility.	2010	22282687
Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.	2010	20617420
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.	2009-12	19958867
New P2Y12 antagonists.	2009-09	19550317
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.	2009-04	19336638

Patents

Sample Use Guides

In Vivo Use Guide

80-mg intravenous bolus of elinogrel was given immediately before percutaneous coronary intervention, followed by twice-daily oral elinogrel administration of 50, 100, or 150 mg for 60 days

Route of Administration: Other

In Vitro Use Guide

When two concentrations of elinogrel (2.5 or 5.0 mmol/l) were added in vitro to the blood of diabetic patients, an anti-thrombotic effect was observed, supporting evidence that elinogrel may overcome the limitation of poor clopidogrel response.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:18:25 GMT 2025` Edited by `admin` on `Wed Apr 02 08:18:25 GMT 2025`
Record UNII	915Y8E749J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ELINOGREL [MI]

Preferred Name

English

ELINOGREL

Official Name

English

Elinogrel [WHO-DD]

Common Name

English

PRT 060128

Code

English

elinogrel [INN]

Common Name

English

5-CHLORO-N-((4-(6-FLUORO-7-(METHYLAMINO)-2,4-DIOXO-1,4-DIHYDROQUINAZOLIN-3(2H)-YL)PHENYL)CARBAMOYL)THIOPHENE-2-SULFONAMIDE

Systematic Name

English

ELINOGREL [USAN]

Common Name

English

PRT-060128

Code

English

2-THIOPHENESULFONAMIDE, 5-CHLORO-N-(((4-(6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL)PHENYL)AMINO)CARBONYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C80483